Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study.
- DOI
- 10.1016/j.esmoop.2026.108343
- Published
- 2026 Sep
- Container
- ESMO open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmoop.2026.108343,
title = {Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study.},
author = {Coutzac C and Zaanan A and de Montfort A and Soularue E and Cohen R and Le Sourd S and Piessen G and Hautefeuille V and Ben Abdelghani M and Blanc E and Svrcek M and Samalin E and Pérol D and de la Fouchardière C},
year = {2026},
journal = {ESMO open},
doi = {10.1016/j.esmoop.2026.108343},
url = {https://doi.org/10.1016/j.esmoop.2026.108343}
}RIS
TY - JOUR TI - Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study. AU - Coutzac C AU - Zaanan A AU - de Montfort A AU - Soularue E AU - Cohen R AU - Le Sourd S AU - Piessen G AU - Hautefeuille V AU - Ben Abdelghani M AU - Blanc E AU - Svrcek M AU - Samalin E AU - Pérol D AU - de la Fouchardière C PY - 2026 JO - ESMO open DO - 10.1016/j.esmoop.2026.108343 UR - https://doi.org/10.1016/j.esmoop.2026.108343 ER -
APA
C, C., A, Z., A, D. M., E, S., R, C., S, L. S., G, P., V, H., M, B. A., E, B., M, S., E, S., D, P., & C, D. L. F. (2026). Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108343
Source records
- pubmed · retrieved 2026-09-25T08:52:47.741Z